Back to top

cell-therapy: Archive

Zacks Equity Research

Allogene's Q1 Earnings In Line With Estimates, Sales Nil

ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.

AGENNegative Net Change ADPTNegative Net Change ALLONegative Net Change ELEVPositive Net Change

Zacks Equity Research

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.

BEAMPositive Net Change ADPTNegative Net Change IOVAPositive Net Change ELEVPositive Net Change

Ekta Bagri

Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.

BMYNegative Net Change MRKPositive Net Change GILDPositive Net Change

Urmimala Biswas

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.

REGNPositive Net Change ALCPositive Net Change GKOSPositive Net Change